Postoperative Restrictive Opioid Protocols and Durable Changes in Opioid Prescribing and Chronic Opioid Use.


Journal

JAMA oncology
ISSN: 2374-2445
Titre abrégé: JAMA Oncol
Pays: United States
ID NLM: 101652861

Informations de publication

Date de publication:
01 02 2023
Historique:
pmc-release: 05 01 2024
pubmed: 6 1 2023
medline: 22 2 2023
entrez: 5 1 2023
Statut: ppublish

Résumé

Changes in postsurgical opioid prescribing practices may help reduce chronic opioid use in surgical patients. To investigate whether postsurgical acute pain across different surgical subspecialties can be managed effectively after hospital discharge with an opioid supply of 3 or fewer days and whether this reduction in prescribed opioids is associated with reduced new, persistent opioid use. In this prospective cohort study with a case-control design, a restrictive opioid prescription protocol (ROPP) specifying an opioid supply of 3 or fewer days after discharge from surgery along with standardized patient education was implemented across all surgical services at a tertiary-care comprehensive cancer center. Participants were all patients who underwent surgery from August 1, 2018, to July 31, 2019. Main outcomes were the rate of compliance with the ROPP in each surgical service, the mean number of prescription days and refill requests, type of opioid prescribed, and rate of conversion to chronic opioid use determined via a state-run opioid prescription program. Postsurgical complications were also measured. A total of 4068 patients (mean [SD] age, 61.0 [13.8] years; 2528 women [62.1%]) were included, with 2017 in the pre-ROPP group (August 1, 2018, to January 31, 2019) and 2051 in the post-ROPP group (February 1, 2019, to July 31, 2019). The rate of compliance with the protocol was 95%. After implementation of the ROPP, mean opioid prescription days decreased from a mean (SD) of 3.9 (4.5) days in the pre-ROPP group to 1.9 (3.6) days in the post-ROPP group (P < .001). The ROPP implementation led to a 45% decrease in prescribed opioids after surgery (mean [SD], 157.22 [338.06] mean morphine milligram equivalents [MME] before ROPP vs 83.54 [395.70] MME after ROPP; P < .001). Patients in the post-ROPP cohort requested fewer refills (367 of 2051 [17.9%] vs 422 of 2017 [20.9%] in the pre-ROPP cohort; P = .02). There was no statistically significant difference in surgical complications. The conversion rate to chronic opioid use decreased following ROPP implementation among both opioid-naive patients with cancer (11.3% [143 of 1267] to 4.5% [118 of 2645]; P < .001) and those without cancer (6.1% [19 of 310] to 2.7% [16 of 600]; P = .02). In this cohort study, prescribing an opioid supply of 3 or fewer days to surgical patients after hospital discharge was feasible for most patients, led to a significant decrease in the number of opioids prescribed after surgery, and was associated with a significantly decreased conversion to long-term opioid use without concomitant increases in refill requests or significant compromises in surgical recovery.

Identifiants

pubmed: 36602807
pii: 2800244
doi: 10.1001/jamaoncol.2022.6278
pmc: PMC9857779
doi:

Substances chimiques

Analgesics, Opioid 0
MME 78185-58-7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

234-241

Auteurs

Emese Zsiros (E)

Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Jason Ricciuti (J)

Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Department of Gynecologic Oncology, St Louis University Hospital, SSM Health, St Louis, Missouri.

Steven Gallo (S)

Information Technology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Deanna Argentieri (D)

Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Kristopher Attwood (K)

Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Wenyan Ji (W)

Department of Biostatistics and Health Data Science, Virginia Tech, Roanoke, Virginia.

Alan Hutson (A)

Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Paul Visco (P)

Information Technology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Devon Coffey (D)

University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, New York.

Grazyna Riebandt (G)

Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Jaron Mark (J)

The START Center for Cancer Care, San Antonio, Texas.

Aaron Varghese (A)

Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Suzanne M Hess (SM)

Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Thomas Furlani (T)

Information Technology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Andrew Fabiano (A)

Neuro-Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Mark Hennon (M)

Thoracic Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Sai Yendamuri (S)

Thoracic Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Eric C Kauffman (EC)

Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Kimberly E Wooten (KE)

Head & Neck Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Wesley L Hicks (WL)

Head & Neck Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Jessica Young (J)

Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Kazuaki Takabe (K)

Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Kunle Odunsi (K)

Department of Obstetrics and Gynecology, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois.

Amy A Case (AA)

Supportive Care, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Brahm H Segal (BH)

Department of Internal Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Candace S Johnson (CS)

Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Boris Kuvshinoff (B)

Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Steven Nurkin (S)

Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Gyorgy Paragh (G)

Department of Dermatology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Oscar de Leon-Casasola (O)

Division of Pain Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH